Liu Mei, Wu Hai-Yan, Li Jian, Ou Meng-Yu, Sun Shu-Fang, Tang Ying, Zhao Xiu-Juan
Department of Radiation Oncology Center Chongqing University Cancer Hospital Chongqing China.
Department of Ultrasound Medicine Chongqing Shaping District People's Hospital Chongqing China.
Precis Radiat Oncol. 2023 Jun 1;7(2):137-141. doi: 10.1002/pro6.1194. eCollection 2023 Jun.
This study investigated the analgesic effects in patients with cervical cancer during brachytherapy.
In this prospective study, 100 patients with cervical cancer who were admitted to Chongqing University Cancer Hospital between July 2021 and April 2022 were randomly divided into an analgesia group (n = 50) and a control group (n = 50). The visual analog scale (VAS) scores at applicator placement-T1, CT-scan-T2, and removal -T3, self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores before brachytherapy, short-term clinical efficacy, and patient satisfaction were compared between the two groups.
The VAS score of the analgesia group was significantly different at T1 (0 vs. 4.34±1.02, = 67.40, < 0.001), but not in the control group; however, there was no significant difference between the two groups at T2 ( = -0.49, = 0.623) and T3 ( = -0.12, = 0.912). The SAS and SDS scores first decreased and then increased in the analgesic group and increased in the control group with increasing brachytherapy time. Except for the first measurement, the differences between the two groups were statistically significant (all < 0.001). The application of interstitial implantation ( = 0.027), local efficacy ( = 0.047), and patient satisfaction rates ( = 0.025) were higher in the analgesic group than in the control group.
Analgesia can relieve pain, maintain physical and mental health, and improve outcomes and patient satisfaction rates for cervical cancer.
本研究调查了宫颈癌患者近距离放疗期间的镇痛效果。
在这项前瞻性研究中，将2021年7月至2022年4月入住重庆大学附属肿瘤医院的100例宫颈癌患者随机分为镇痛组（n = 50）和对照组（n = 50）。比较两组在施源器放置时（T1）、CT扫描时（T2）和取出时（T3）的视觉模拟量表（VAS）评分、近距离放疗前的自评焦虑量表（SAS）和自评抑郁量表（SDS）评分、短期临床疗效及患者满意度。
镇痛组在T1时VAS评分有显著差异（0 vs. 4.34±1.02，Z = 67.40，P < 0.001），而对照组无差异；然而，两组在T2时（Z = -0.49，P = 0.623）和T3时（Z = -0.12，P = 0.912）无显著差异。随着近距离放疗时间增加，镇痛组的SAS和SDS评分先降低后升高，而对照组升高。除首次测量外，两组间差异均有统计学意义（均P < 0.001）。镇痛组间质植入的应用（P = 0.027）、局部疗效（P = 0.047）及患者满意率（P = 0.025）均高于对照组。
镇痛可缓解疼痛，维持身心健康，并改善宫颈癌的治疗效果及患者满意率。
